Additive effects of β-blockers on renin-angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization

Circulation Journal

Volumn 75, Issue 8, 2011, Pages 1982-1991

  Konishi, Masanori ^a   Haraguchi, Go ^a   Yoshikawa, Shunji ^a   Kimura, Shigeki ^a   Inagaki, Hiroshi ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

blocker; Acute myocardial infarction; Cardiac function; Prognosis

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GELATINASE A; GELATINASE B; IMIDAPRIL; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; TELMISARTAN; TEMOCAPRIL; VALSARTAN;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BISOPROLOL; BLOOD PRESSURE; CARBAZOLES; DRUG SYNERGISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPANOLAMINES; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 79960766650     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1241     Document Type: Article

References (29)

1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
2. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241.
3. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial: The SAVE Investigators. N Engl J Med 1992; 327: 669-677.
4. Scheen AJ, Krzesinski JM. ONTARGET: Similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events. Rev Med Liege 2008; 63: 213-219 (in French).
5. Snow PJ. Effect of propranolol in myocardial infarction. Lancet 1965; 2: 551-553.
6. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
7. Hong YJ, Jeong MH, Hwang SH, Yun NS, Lee SR, Hong SN, et al. Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. Circ J 2006; 70: 1269-1274.
8. Yoshitomi Y, Kojima S, Yano M, Sugi T, Matsumoto Y, Kuramochi M. Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: An angiographic study in patients with maintained vessel patency. Am Heart J 2000; 140: E27.
9. Ivanova LA, Kanorskii SG, Rostovtseva ON, Halil Sufian B, Galenko-Yaroshevskii PA. Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors: Cardiohemodynamic effects and impact for prognosis. Bull Exp Biol Med 2004; 138: 301-304.
10. Williams RE. Beta blockade in the post-myocardial infarction setting: Pharmacologic rationale and clinical evidence. Prev Cardiol 2006; 9: 96-101.
11. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction: A matter of dose. N Engl J Med 2003; 349: 1963-1965.
12. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
13. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-1549.
14. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-372.
15. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10: 328-333.
16. Schafers RF, Poller U, Ponicke K, Geissler M, Daul AE, Michel MC, et al. Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 239-249.
17. McDevitt DG. In vivo studies on the function of cardiac beta-adrenoceptors in man. Eur Heart J 1989; 10: 22-28.
18. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
19. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 2006; 70: 1905-1913.
20. Ito H, Nagatomo Y, Kohno T, Anzai T, Meguro T, Ogawa S, et al. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. Circ J 2010; 74: 1578-1583.
21. Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, et al. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 2005; 96: 31-34.
22. Wu TC, Chen YH, Leu HB, Chen YL, Lin FY, Lin SJ, et al. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. Free Radic Biol Med 2007; 43: 1508-1522.
23. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101: 122-124.
24. Gao F, Chen J, Lopez BL, Christopher TA, Gu J, Lysko P, et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 2000; 406: 109-116.
25. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
26. Ishiguro H, Ikeda T, Abe A, Tsukada T, Mera H, Nakamura K, et al. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008; 49: 281-293.
27. Konishi M, Haraguchi G, Kimura S, Inagaki H, Kawabata M, Hachiya H, et al. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. Circ J 2010; 74: 1127-1134.
28. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure: Special reference to transcardiac [corrected] gradient of norepinephrine. Circ J 2009; 73: 2270-2275.
29. Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969-973.